VectivBio (NASDAQ:VECT) Downgraded by SVB Securities to “Market Perform”

SVB Securities lowered shares of VectivBio (NASDAQ:VECT – Get Rating) from an outperform rating to a market perform rating in a report published on Tuesday, The Fly reports.

A number of other research analysts also recently commented on the stock. Piper Sandler raised their target price on shares of VectivBio from $23.00 to $25.00 and gave the company an overweight rating in a research report on Thursday, April 20th. Credit Suisse Group downgraded VectivBio from an outperform rating to a neutral rating in a research report on Monday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, VectivBio presently has an average rating of Moderate Buy and a consensus price target of $24.33.

VectivBio Stock Up 1.8 %

Shares of NASDAQ VECT opened at $16.50 on Tuesday. The company has a quick ratio of 9.14, a current ratio of 9.14 and a debt-to-equity ratio of 0.05. The business has a fifty day simple moving average of $9.94 and a two-hundred day simple moving average of $8.89. VectivBio has a twelve month low of $4.25 and a twelve month high of $16.60.

Institutional Investors Weigh In On VectivBio

A number of large investors have recently modified their holdings of VECT. Frazier Life Sciences Management L.P. acquired a new stake in shares of VectivBio during the fourth quarter worth $11,481,000. Barclays PLC purchased a new position in shares of VectivBio in the third quarter worth about $47,000. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of VectivBio in the first quarter worth about $478,000. Bank of America Corp DE raised its stake in shares of VectivBio by 17.6% in the first quarter. Bank of America Corp DE now owns 85,484 shares of the company’s stock worth $403,000 after purchasing an additional 12,802 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of VectivBio by 6.9% in the first quarter. Geode Capital Management LLC now owns 24,647 shares of the company’s stock worth $212,000 after acquiring an additional 1,593 shares during the period. Hedge funds and other institutional investors own 90.52% of the company’s stock.

VectivBio Company Profile

(Get Rating)

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy.